|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:comparator
|
gptkb:warfarin
|
|
gptkbp:conditionStudied
|
gptkb:atrial_fibrillation
|
|
gptkbp:eligibility
|
non-valvular atrial fibrillation
CHADS2 score ≥1
|
|
gptkbp:endDate
|
2008
|
|
gptkbp:enrollment
|
707
|
|
gptkbp:fullName
|
Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PROTECT AF
|
|
gptkbp:location
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:number
|
NCT00129545
|
|
gptkbp:period
|
Phase 3
|
|
gptkbp:principalInvestigator
|
David R. Holmes Jr.
|
|
gptkbp:publicationYear
|
2009
|
|
gptkbp:publishedIn
|
gptkb:Lancet
|
|
gptkbp:result
|
stroke prevention
cardiovascular death
Lower hemorrhagic stroke with Watchman device
systemic embolism prevention
Higher procedural complications with Watchman device
Watchman device non-inferior to warfarin for stroke prevention
|
|
gptkbp:sponsor
|
gptkb:Boston_Scientific
|
|
gptkbp:startDate
|
2005
|
|
gptkbp:studiedIntervention
|
Watchman device
|
|
gptkbp:studyType
|
gptkb:clinical_trial
|
|
gptkbp:bfsParent
|
gptkb:WATCHMAN_Left_Atrial_Appendage_Closure_Device
|
|
gptkbp:bfsLayer
|
7
|